SEMA3B

Across TCGA pan-cancer cohorts, SEMA3B mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SEMA3B’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where SEMA3B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SEMA3B is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC, LUAD, and CCRCC are the cancer types where SEMA3B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SEMA3B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	−1.003	<.001	9	view →
LUAD	Female	All	−0.721	<.001	9	view →
CCRCC	Male	III,IV	−0.725	<.001	6	view →
PDAC	All	II,III,IV	−0.473	<.001	5	view →
COAD	All	All	−0.926	<.001	4	view →
HNSC	Male	All	−0.647	.032	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SEMA3B–LSCC

Open the LSCC breakdown →